The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.

Curr Cardiol Rev · 2017 · PMC5730960 · PMID 28782494

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The study showed that treatment with atorvastatin 10 mg/day and 20 mg/day showed a trend towards an incremental increase in PCSK9 levels at 8 weeks, with both doses achieving lipid-lowering effects.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.